Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 4
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 3(2)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07549386Phase 3Completed

Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.

Role: lead

NCT06313268Completed

Safety of Effivia®, a Bevacizumab Biosimilar

Role: lead

NCT05995912Phase 2Completed

Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain

Role: lead

NCT04406246Phase 4Completed

Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide

Role: collaborator

NCT03460743Phase 3Completed

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

Role: lead

All 5 trials loaded